HD-OPM Archive
Topics › Statins

All 25 statin RCTs through 2016 show benefit: about 40% less MACE per 75 mg/dL LDL drop

Louis Nervegna · May 11, 2025 · ♥ 25 reactions · 12 comments · original Facebook post
StatinsLDL, ApoB & lipid panelHeart attack, stroke & procedures
AI summary & key facts

Louis shares a graph of every statin RCT up to 2016 that showed a significant effect on cardiovascular outcomes, excluding trials under 6 months or with under 50 events. On average, a ~75 mg/dL (1.9 mmol/L) LDL reduction cut heart attack and stroke risk about 40% vs placebo, with primary-prevention trials showing even larger reductions than secondary-prevention trials.

One of the group members asked for a list of all the randomized controlled trials with statins that showed a statistically-significant effect on lowering rates of heart attack, stroke, or cardiovascular mortality.

This graph shows all 25 of them, as of 2016.

In aggregate, a lowering in LDL level of about 75mg/dL (1.9mmol/L) from the statin reduced the risk of having a heart attack or stroke (MACE) by about 40% on average, as compared to people taking a placebo.

The paper where the graph came from is linked to in the post.

Each number on the graph corresponds to a journal article in the reference section of the paper that is linked to. You can click each of these references in the paper to read the individual study. You can do this for each one of the 25 studies plotted on the graph. For example, to read study #47 on the graph, go to the reference section of the paper and click on the article numbered as 47. Note that you must open the full paper as a PDF to see the references. If you have any questions about how to do any of this, I can answer them in the comments.

Research cited

As of 2016, twenty five different randomized-controlled trials each independently showed that statins reduce major adverse cardiac events (MACE), like heart attacks and strokes.

Here are all 25 of them— summarized on one graph.

There is no cherry picking here. This is every RCT conducted on statins up to 2016– except those lasting less than 6 months or with less than 50 adverse clinical events— only very short or small trials were excluded.

A lowering in LDL level of about 75mg/dL (1.9mmol/L) from the statin reduced the risk of having a heart attack or stroke (MACE) by about 40% on average, as compared to people taking a placebo.

(For example, someone with an LDL of 100mg/dL taking a statin in these trials would have a 40% lower risk of having a heart attack or stroke (MACE) on average than someone with LDL of 175mg/dL taking a placebo.)

To understand how this translates into a large reduction in absolute risk over the long term, see this post:

↪ Statin absolute risk reduction is cumulative: 1-2% in trials, far more over a lifetime

Seven of these clinical trials were primary prevention trials— participants who never had a heart attack or stroke before— as shown on the graph (circles). Notice that the risk reductions for the 7 primary prevention trials (circles) were even larger than the risk reductions for the 18 secondary prevention trials (squares).

Since 2016, even more clinical trials on statins have corroborated this.

This is WHY statins are now the standard of care in cardiology.

Note that 40mg/dL of LDL corresponds to about 1mmol/L.

Reference for this graph:

PaperAssociation Between Lowering LDL C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta analysisresearchgate.net

#statinsHD #statinrctsHD #ldlrctsHD #ldlHD #cacHD

No photo description available.
← newer: Statin absolute risk reduction looks small over 5 years but older: 18 large RCTs plus cohort and Mendelian studies show a strai →